Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) ended Thursday session in green amid volatile trading. The shares closed up +6.79 points or 13.87% at $55.73 with 21.13 million shares getting traded. Post opening the session at $51.95, the shares hit an intraday low of $51.95 and an intraday high of $56.80 and the price vacillated in this range throughout the day. The company has a market cap of $4.64 billion and the numbers of outstanding shares have been calculated to be 47.90 million shares.
Sarepta Therapeutics Inc (SRPT) on September 21, 2016 announced that the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) has issued two favorable decisions for Sarepta in the composition of matter patent interferences for exon 51 (Interference No. 106,008) and exon 53 (Interference No. 106,007). These decisions, subject to appeal, finally refused all of BioMarin’s claims in the exon 51 and exon 53 composition of matter interferences that, if granted, could have formed a basis for a claim of infringement against eteplirsen and SRP-4053. The PTAB decision for exon 53 allows BioMarin to obtain a narrow composition of matter claim, however, SRP-4053 does not infringe this claim. The PTAB ended the exon 51 interference in our favor based on a statute of limitations bar.
Accordingly, the PTAB did not decide the patentability of the Sarepta exon 51 patents involved in the interference (U.S. Patent Nos. 7,807,816 and 7,960,541). Although the PTAB did decide to cancel the Sarepta exon 53 patent involved in the interference (U.S. Patent No. 8,455,636), that exon 53 decision does not negatively impact Sarepta’s key composition of matter patent protection for EXONDYS 51 and SRP-4053 (U.S. Patent Nos. 9,018,368 and 9,024,007, respectively). Neither of these key patents are involved in any pending interferences and are presumed valid and enforceable. These patents expire in June 2025, not including any potential patent term extension or regulatory exclusivity that would extend this date.
Shares of Skyline Medical Inc (NASDAQ:SKLN) ended Thursday session in red amid volatile trading. The shares closed down -0.003 points or -1.52% at $0.175 with 7.78 million shares getting traded. Post opening the session at $0.18, the shares hit an intraday low of $0.17 and an intraday high of $0.19 and the price vacillated in this range throughout the day. The company has a market cap of $12.78 million and the numbers of outstanding shares have been calculated to be 81.80 million shares.
Skyline Medical Inc (SKLN) on Sept. 08, 2016 announced the appointment of Paul Sweetnam, Ph.D. to the Company’s Medical Advisory Board (MAB). Dr. Sweetnam brings to Skyline’s MAB more than 25 years of executive and entrepreneurial experience in the pharmaceutical and biotechnology industries. In addition, Dr. Sweetnam has established an extensive network of scientific collaborators within academia, the government and industry.
Skyline Medical’s MAB was formed in July 2013 and provides guidance and advice to the Company to support its product development goals. Including Dr. Sweetnam, the MAB has five members.
“We are delighted that a scientist of Dr. Sweetnam’s stature has agreed to join our MAB,” said Dr. Carl Schwartz, chairman and interim chief executive officer of Skyline Medical. “His impressive credentials include a track record of identifying and integrating disruptive technologies such as high-throughput and profile screening into the drug discovery and development process. We are looking forward to being able to leverage Dr. Sweetnam’s capabilities as we explore the use of the STREAMWAY System filter as a method of sample collection for rapid diagnostics and biomarker identification in the operating room.”